The Zhitong Finance App learned that BOC International released a research report stating that it raised the target price of Hanson Pharmaceuticals (03692.HK) to HK$46 to maintain the “buy” rating and key recommendations for the prescription drug industry. The bank also raised the company's 2026-2028 revenue and profit forecast, mainly based on strong revenue and profit margin performance in the first half of 2026, and is expected to usher in a new wave of innovative drug launches starting in 2027.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.